# Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

> **NCT05396859** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 13 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Decitabine and Cedazuridine
- **DRUG:** Entrectinib
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT05396859
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-28
- **Primary completion:** 2024-06-10
- **Final completion:** 2026-12-31
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05396859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05396859, "Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05396859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*